AHC Hardwood Group Launches New Website and Brand Identity

Atlanta Hardwood Corporation, a leader in the U.S. hardwood industry for more than 70 years, has officiallyrebranded and launched a new website under its updated market identity: AHC Hardwood Group. Atlanta Hardwood Corporation rebrands and launches a new website under its updated market identity: AHC Hardwood Group. The rebranding reflects the company's evolution from traditional […]

Canada risks missing out on billions in critical mineral investment without swift policy changes: report

Governments can attract investment, accelerate development, and capture opportunities arising from the global energy transition by sharing financial risks while upholding Indigenous rights and environmental protections New research from the Canadian Climate Institute finds governments should act swiftly to de-risk critical minerals investment and accelerate project timelines-without cutting corners on Indigenous rights and environmental protections-to

Critical One Makes Strategic Uranium Asset Divestment

Critical One Makes Strategic Uranium Asset Divestment GlobeNewswire June 12, 2025 TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company“) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that Dark Star Minerals Inc. (“Dark Star”) (CSE: BATT) (FSE: P0W), a well-managed, uranium-focused,

New trailer type gets strong underride guard

New trailer type gets strong underride guard Stoughton extends IIHS-award-winning underride protection to container shipping GlobeNewswire June 12, 2025 ARLINGTON, Va., June 12, 2025 (GLOBE NEWSWIRE) — A Stoughton chassis designed for container transport is the first of its kind to qualify for the Insurance Institute for Highway Safety's TOUGHGUARD award for superior underride protection.

Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC

— 66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days — 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions — Building trust among patients and healthcare professionals around AI key to driving wider adoption

Coaching seen as key priority for the future workplace, yet more than half of business leaders lack the formal training

— Coaching (34%) emerges as one of the top initiatives business leaders foresee theirorganisation prioritising in the next five years. — Majority of business leaders (94%) and employees (92%) believe that coaching benefits individuals across all levels and job roles, with most viewing it as essential for personal and professional development (85% of leaders, 80%

Global Fatty Liver Day 2025: Elevating Liver Health in the Metabolic Health Conversation

Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) — On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one of the most widespread yet under-addressed health threats of our time: fatty liver disease, increasingly referred to as steatotic liver disease (SLD) in clinical settings. Hosted annually by Global Liver Institute

Global Fatty Liver Day 2025: Elevating Liver Health in the Metabolic Health Conversation

Global Fatty Liver Day 2025: Elevating Liver Health in the Metabolic Health Conversation Global Liver Institute Calls for Urgent Action as Fatty Liver Disease Prevalence Surges Worldwide GlobeNewswire June 12, 2025 Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) — On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one

Kelun-Biotech’s Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

SichuanKelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) today announced that the Company has received a clinical trial notice approving the investigational new drug application for the its CLDN18.2-directed antibody-drug conjugate (ADC) SKB315 in combination of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody (mAb) tagitanlimab for the first-line treatment of gastric cancer / gastro-oesophageal junction cancer

Scroll to Top